Provided herein is A compound of Formula I:

##STR00001## or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

Systems, methods, and apparatuses for debriding a tissue site are described. The system includes a manifold and a cover adapted to form a sealed space over the tissue site for providing negative pressure. The system also includes a debridement tool positioned between the manifold and the tissue site. The debridement tool having a tissue-facing surface and a plurality of holes separated from each other by walls. The walls have transverse surfaces extending between the tissue-facing surface and an opposite surface that form cutting edges. The holes have a perforation shape factor that allows the holes to collapse from a relaxed position to a contracted position in response to the application and removal of negative pressure from the sealed space. The cutting edges debride the tissue site in response to movement between the relaxed position and the contracted position.

The present invention provides a process for producing the compound having the structure: ##STR00001##
comprising (a) reacting a compound having the structure: ##STR00002## with a compound having the structure: ##STR00003## in the presence of a first organic solvent under conditions sufficient to produce the compound,
wherein the first organic solvent is a substituted benzene.

The present invention provides a process for producing the compound having the structure: ##STR00001##
comprising (a) reacting a compound having the structure: ##STR00002## with a compound having the structure: ##STR00003## in the presence of a first organic solvent under conditions sufficient to produce the compound,
wherein the first organic solvent is a substituted benzene.

The invention provides a lighting device (1) comprising (a) a light source (10) configured to generate light source light (11), and (b) a light converter (100) configured to convert at least part of the light source light (11) into visible converter light (111), wherein the light converter (100) comprises a matrix (120) containing a luminescent material (140) based on derivatives of benzimidazoxanthenoisoquinolinone. The lighting device may further comprise a further luminescent material (130).

Provided herein is A compound of Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

Provided herein is A compound of Formula I:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.